Evommune, Inc.
EVMN
Rank in Stocks
#15191
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Share Price
$7.65
Last synced: 2026-11-09
Market Cap
$277.63M
Change (1 day)
15.04%
Change (1 year)
-60.71%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Evommune, Inc. (EVMN)
Category
Healthcare
EPS for Evommune, Inc. (EVMN)
EPS as of June 2026 TTM: $-3.37
According to Evommune, Inc.'s latest financial reports, its current EPS (TTM) is $-3.37. At the end of 2025 the company had an EPS of $-11.22, a decrease compared to its 2024 EPS of $-2.27.
EPS history for Evommune, Inc. from 2023 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.37 | -69.96% |
| 2025 | $-11.22 | 394.27% |
| 2024 | $-2.27 | 100.88% |
| 2023 | $-1.13 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -564.69% |
US
|
|
| $-7.07 | 109.79% |
US
|
|
| $-5.29 | 56.97% |
AU
|
|
| $12.88 | -482.20% |
BE
|
|
| $21.56 | -739.76% |
NL
|
Questions about Evommune, Inc.'s earnings per share (EPS)
What is Evommune, Inc.'s earnings per share (EPS)?
Evommune, Inc.'s earnings per share (EPS) over the last twelve months is $-3.37, as of Jun 2026.
What was Evommune, Inc.'s earnings per share (EPS) in 2025?
In 2025, Evommune, Inc.'s earnings per share (EPS) was $-11.22, compared with $-2.27 in 2024.
How has Evommune, Inc.'s earnings per share (EPS) changed since 2023?
From 2023 to 2025, Evommune, Inc.'s earnings per share (EPS) was highest in 2023 ($-1.13) and lowest in 2025 ($-11.22).
How does Evommune, Inc.'s earnings per share (EPS) compare with similar companies?
Evommune, Inc.'s earnings per share (EPS) ($-3.37) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.